Sepetaprost
![]() | |
| Clinical data | |
|---|---|
| Other names | STN-1012600 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C26H36F2O6 |
| Molar mass | 482.565 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Sepetaprost is an investigational new drug that is being evaluated for the treatment of open angle glaucoma and ocular hypertension.[1] It is an agonist of the prostaglandin EP3 and F receptors.[2]
References
- ^ "Sepetaprost - Santen Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
- ^ Sharif NA, Odani-Kawabata N, Lu F, Pinchuk L (April 2023). "FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma". Experimental Eye Research. 229: 109415. doi:10.1016/j.exer.2023.109415. PMID 36803996.
